Oxidant/antioxidant parameters and their relationship with medical treatment in multiple myeloma

Basit Öğe Kaydı
dc.authoridKAYA, Emin/0000-0001-8605-8497
dc.authoridErkurt, Mehmet Ali/0000-0002-3285-417X
dc.authorwosidKAYA, Emin/W-2951-2017
dc.authorwosidErkurt, Mehmet Ali/ABI-7232-2020
dc.contributor.authorKuku, I
dc.contributor.authorAydogdu, I
dc.contributor.authorBayraktar, N
dc.contributor.authorKaya, E
dc.contributor.authorAkyol, O
dc.contributor.authorErkurt, MA
dc.date.accessioned2024-08-04T20:13:40Z
dc.date.available2024-08-04T20:13:40Z
dc.date.issued2005
dc.departmentİnönü Üniversitesien_US
dc.description.abstractMultiple myeloma (MM) is a neoplastic disorder characterized by monoclonal multiplying of plasma cells. Although radiation, environmental factors, viruses and other factors have been suggested as potential causes of the disease, the aetiopathogenesis of MM is still obscure. This clinical study was designed to investigate the role of reactive oxygen species (ROS) in the aetiopathogenesis of the disease and the possible relationships between treatment and ROS production. For this purpose, erythrocyte superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), and catalase (CAT) activities as well as plasma nitric oxide (NO) and malondialdehyde (MDA) levels were measured in 14 MM patients newly diagnosed at stage III. The relationship between the above-mentioned parameters and vincristine-adriamycin-dexamethasone (VAD) therapy were also investigated in the same patients. All the enzyme activities and the parameters of oxidative stress were found to be significantly reduced after VAD therapy. These findings suggest that ROS may be involved in the aetiopathogenesis of MM. Further investigations with a larger cohort of MM patients are needed to provide definitive data about the role of ROS in MM and the alternative therapeutic approaches to MM. Copyright (C) 2004 John Wiley Sons, Ltd.en_US
dc.identifier.doi10.1002/cbf.1127
dc.identifier.endpage50en_US
dc.identifier.issn0263-6484
dc.identifier.issn1099-0844
dc.identifier.issue1en_US
dc.identifier.pmid15386538en_US
dc.identifier.scopus2-s2.0-11244325899en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage47en_US
dc.identifier.urihttps://doi.org/10.1002/cbf.1127
dc.identifier.urihttps://hdl.handle.net/11616/93770
dc.identifier.volume23en_US
dc.identifier.wosWOS:000226038500007en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofCell Biochemistry and Functionen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectmultiple myelomaen_US
dc.subjectsuperoxide dismutaseen_US
dc.subjectcatalaseen_US
dc.subjectglutathione peroxidaseen_US
dc.subjectmalondialdehydeen_US
dc.subjectnitric oxideen_US
dc.titleOxidant/antioxidant parameters and their relationship with medical treatment in multiple myelomaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu